Search
Uniqure NV
QUREAdd to Watchlist
43.630USD
+1.440+3.41%
Close 07-31 16:00（ET）Quotes delayed by 15 min
3.03BMarket Cap
LossP/E TTM
More Details of Uniqure NV Company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Uniqure NV Info
Ticker SymbolQURE
Company nameUniqure NV
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Number of employees209
Security typeOrdinary Share
Fiscal year-endFeb 05
AddressPaasheuvelweg 25a
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1105 BP
Phone31202406000
Websitehttps://www.uniqure.com/
Ticker SymbolQURE
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Company Executives of Uniqure NV
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
42.30K
-50.67%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
27.52K
+20.19%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
25.93K
+21.43%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
42.30K
-50.67%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
FAQs
Who are the top five shareholders of Uniqure NV?
The top five shareholders of Uniqure NV are: Mr. Christian Klemt, CPA
How many institutions hold shares of Uniqure NV (QURE)?
As of 2026Q1, 481 institutions hold shares of Uniqure NV, with a combined market value of approximately 65.80M, accounting for 104.34% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1601871.00.